Chris Ullman

Chris Ullman is a seasoned biotechnology executive and entrepreneur with extensive experience in cancer research and development. As the CEO and Founder of Stratosvir Limited since April 2021, Chris Ullman leads efforts in developing viral immunotherapy aimed at improving treatment for solid tumors. In addition to this role, Chris Ullman serves as a Founding Analyst at Deep Science Ventures, where opportunities in oncology are identified to transform cancer treatment. At Paratopix Ltd., established as a Director and Founder, Chris Ullman provides consulting services on scientific strategy and business development to small biotech firms. Other significant positions include Commercial Director at XenoVida, Scientific Advisor for Cancer Targeting Systems, and Project Manager for Business Development at Cagen Ltd. With a background that includes leadership roles at Isogenica Ltd. and Gendaq Ltd., along with research at the Royal Free Hospital NHS Trust, Chris Ullman has demonstrated expertise in synthetic biology, immuno-oncology, and the commercialization of innovative therapeutics.